

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claims 1-17 (Cancelled)

Claim 18 (new): A method of improving the responder rate to or advancing the onset of action of serotonin re-uptake inhibitor (SRI) in the treatment of depressive disorders, anxiety disorders, post-traumatic stress syndrome or premenstrual syndrome, said method comprising combined administration of SRI in a daily amount of at least 0.4 mg, and vitamin B6 component in a daily amount of between 0.01 and 10 mmoles, and wherein the method does not include the application to the brain of an AC pulsed magnetic field of at least 7.5 picotesla flux density for at least 15 minutes.

Claim 19 (new): The method according to claim 18, for use in the treatment of depression or anxiety disorders.

Claim 20 (new): The method according to claim 18, wherein the vitamin B6 component is co-administered in a daily amount of between 0.01 and 10 mmoles to advance the onset of action of the treatment with SRI.

Claim 21 (new): The method according to claim 18, wherein the method comprises at least once daily administration of the SRI and the vitamin B6 component.

Claim 22 (new): The method according to claim 18, wherein the method comprises administration of SRI in a daily amount of between 0.01 and 1 mg per kg bodyweight and vitamin B6 component in a daily amount of between 0.001 and 0.2 mmoles per kg bodyweight.

Claim 23 (new): The method according to claim 18, wherein the vitamin B6 analogue is selected from the group consisting of pyridoxal, pyridoxamine, acetals of pyridoxal, condensation products arising from the reaction of the aldehyde group of pyridoxal with an amine, and addition salts of any of the foregoing members of the group with pharmaceutically acceptable salts.

Claim 24 (new): The method according to claim 18, wherein the dosage ratio of vitamin B6 component to serotonin re-uptake inhibitor is in the range of 0.01 to 1 mmole/mg.

Claim 25 (new): The method according to claim 18, wherein the serotonin re-uptake inhibitor is selected from the group consisting of citalopram, escitalopram, fluoxetine, norfluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine, zimelidine, femoxetine, trazodone, nefazodone, duloxetine, pharmaceutically acceptable salts of these inhibitors and mixtures thereof.

Claim 26 (new): The method according to claim 18, wherein the formulation comprises at least 300 mg of a serotonin precursor selected from the group consisting of L-tryptophan, 5-hydroxytryptophan, precursors thereof and mixtures thereof.

Claim 27 (new): The method according to claim 18, wherein the formulation comprises at least 0.05 mmoles of a salicylate.

Claim 28 (new): The method according to claim 18, wherein the formulation does not contain a narcotic selected from the group consisting of codeine, oxycodone, propoxyphene, pentazocine, morphine, merperidine, levorphanol, methadone and mixtures thereof, in an amount effective to produce analgesia.

Claim 29 (new): The method according to claim 18, wherein the method comprises the at least once daily oral administration of a slow release formulation containing the vitamin B6 component.

Claim 30 (new): A pharmaceutical formulation containing at least 0.4 mg of serotonin re-uptake inhibitor, at least 0.01 mmole of vitamin B6 component and a pharmaceutically acceptable carrier, said vitamin B6 component being contained in a dosage unit that provides a sustained release of the vitamin B6 component.

Claim 31 (new): The pharmaceutical formulation according to claim 30 for oral, rectal, buccal or transdermal administration, comprising a solid dosage form that contains as active agents at least 0.4 mg of serotonin re-uptake inhibitor and at least 0.01 mmole of vitamin B6 component as well as a pharmaceutically acceptable carrier, said dosage form providing a sustained release of the vitamin B6 component.

Claim 32 (new): The pharmaceutical formulation according to claim 31, wherein the solid dosage form provides a sustained release profile wherein less than 50 wt.% of the vitamin B6 component is released from the dosage form within the first 4 hours after administration and more than 80 wt.% of the vitamin B6 component is released from the dosage form within 24 hours.

Claim 33 (new): The pharmaceutical formulation according to claim 31, wherein the solid dosage form releases the vitamin B6 component at a rate of at least 0.001 mmole/hour during the first 4 hours after administration.

Claim 34 (new): The pharmaceutical formulation according to claim 30, wherein the vitamin B6 component and the serotonin re-uptake inhibitor are present in a ratio of between 0.01 and 1 mmole/mg.